Back to Journals » Clinical, Cosmetic and Investigational Dermatology » Volume 13

Sarecycline: A Review of Preclinical and Clinical Evidence

Authors Moore AY, Del Rosso J, Johnson JL, Grada A

Received 22 April 2020

Accepted for publication 15 July 2020

Published 13 August 2020 Volume 2020:13 Pages 553—560

DOI https://doi.org/10.2147/CCID.S190473

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Jeffrey Weinberg


Angela Yen Moore,1,2 James Del Rosso,3,4 Jodi L Johnson,5 Ayman Grada6,7

1Arlington Research Center, Inc., Arlington, TX, USA; 2Baylor University Medical Center, Dallas, TX, USA; 3JDR Dermatology Research/Thomas Dermatology, Las Vegas, NV, USA; 4Touro University Nevada, Henderson, NV, USA; 5Departments of Dermatology and Pathology, Feinberg School of Medicine, Northwestern University, Evanston, IL, USA; 6R&D and Medical Affairs, Almirall (US), Exton, PA, USA; 7Department of Dermatology, Boston University School of Medicine, Boston, MA, USA

Correspondence: Angela Yen Moore
Arlington Research Center, Inc., 711 East Lamar, Suite 200, Arlington, TX 76011, USA
Tel +1 817 795-7546 ext. 328
Email acderm@acderm.com

Abstract: Sarecycline is a tetracycline-derived oral antibiotic, specifically designed for acne, and is approved by the Food and Drug Administration (FDA) in 2018 for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris (AV) in patients 9 years of age and older. It has been decades since a novel systemic antibiotic was approved to treat AV, a disease that affects up to 90% of teenagers and young adults worldwide and lasts well into adulthood. Sarecycline holds promise to yield fewer side effects than other commonly used broad-spectrum tetracyclines, including minocycline and doxycycline. The narrower spectrum of antibacterial activity of sarecycline, which specifically targets C. acnes and some Gram-positive bacteria with little or no activity against Gram-negative bacteria, suggests not only the potential for reduced emergence of antibiotic-resistant bacterial strains but also less disruption of the human gut microflora. Here, we review the key preclinical and clinical evidence on sarecycline.

Keywords: acne vulgaris, antibiotic, narrow spectrum, tetracycline, sarecycline

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]